Background
==========

The contamination of cell cultures by mycoplasmas is a serious problem because these bacteria have multiple effects on cell cultures and also have a significant influence on the results of scientific studies. The mycoplasmas are not harmless bystanders and thus cannot be ignored in the cell cultures.

Various elimination methods were previously reported \[[@B1]-[@B3]\]. These methods are mainly based on four general procedures, physical, chemical, immunological and chemotherapeutic treatment. The physical procedures include heat treatment and filtration. The chemical procedures, treatments to detergents and other chemicals which are effective only against mycoplasmas, but not against host cells. The immunological procedures include *in vitro* co-culture with macrophages and specific anti-mycoplasmas antisera and *in vivo* passage thorough mice. The chemotherapeutic procedures are mainly antibiotics treatments that are kills mycoplasmas.

*Orientia tsutsugamushi*, which is the causative agents of scrub typhus is one of the obligated intracellular bacteria \[[@B4]\]. The mycoplasmas-contaminations of *O. tsutsugamushi* is also very serious in the *in vitro* studies using cell cultures. Furthermore the most effective methods for elimination of mycoplasmas can not be applied for decontamination of *O. tsutsugamushi* strains because these methods also inhibit the growth of *O. tsutsugamushi*. Decontamination methods should have strong effect on mycoplasmas, but have minimum or no effect on *O. tsutsugamushi*. Only the recommended decontamination method is to passage the contaminated *O. tsutsugamushi* strains through mice. Mouse immunity possibly eliminates only mycoplasmas, although *O. tsutsugamushi* can survive in its target cells, mainly endothelial cells, splenocytes and hepatocytes. In fact, homogenized spleen of infected mice is generally used for the next inoculation. However, this method sometimes does not work especially for low virulent strains of *O. tsutsugamushi* because they are generally difficult to propagate in mice.

Some of the antibiotics, which are used for elimination of mycoplasmas from tissue culture, are supposed to have less effect against *O. tsutsugamushi* according to the differences of minimum inhibitory concentrations (MICs) of antibiotics between mycoplasmas \[[@B5]-[@B7]\] and *O. tsutsugamushi*\[[@B8]\]. In this study, we tried to eliminate mycoplasmas from contaminated *O. tsutsugamushi* strains by repeating passages through cell cultures with antibiotics *in vitro*.

Results and discussion
======================

According to the MICs of antibiotics in the previous reports \[[@B5],[@B7]-[@B9]\], we used two antibiotics, lincomycin and ciprofloxacin for elimination of mycoplasmas from the contaminated *O.tsutsugamushi* strains (Table [1](#T1){ref-type="table"}). Both lincomycin and ciprofloxacin are effective against mycoplasmas. Unfortunately there is no available information about the MICs of lincomycin against *O. tsutsugamushi.* However, according to the MICs of lincomycin against gram-negative bacteria \[[@B10]\], lincomycin is supposed to be much less effective against *O. tsutsugamushi* because *O. tsutsugamushi* is one of the gram-negative bacteria. For the example, the MICs of lincomycin against *Escherichia coli*, one of the typical gram gram-negative bacteria are more than 50 times higher than those against mycoplasmas. Ciprofloxacin was also less effective against *O. tsutsugamushi*. The MICs of ciprofloxacin against *O. tsutsugamushi* are about 3 to 200 times higher than those against mycoplasmas (Table [1](#T1){ref-type="table"}).

###### 

Minimum inhibitory concentrations (MICs) of antibiotics used in this study

  **Antibiotics**   **Drug class**   **MICs against*Orientia***^**a)**^   **MICs against mycoplasmas**^**b)**^
  ----------------- ---------------- ------------------------------------ --------------------------------------
  Lincomycin        Lincosamide      No available data                    **0.25--2 μg/mL**
  Ciprofloxacin     New Quinolone    **6.25--25 μg/mL**                   **0.125--2 μg/ml**
  Gentamicin        Aminoglycoside   No available data^c)^                2.5--500 μg/mL
  Kanamicin         Aminoglycoside   No available data                    2.5--500 μg/mL
  Minocycline       Tetracycline     0.024--0.195 μg/mL                   0.016--32 μg/mL

MICs were obtained from previous reports. a) from \[[@B8]\] and b) from \[[@B5]-[@B7]\].

c\) Gentamycin was not effective against *Orinetia tsutsugamushi* in a mouse model \[[@B25]\].

Our result of the direct sequencing showed that Ikeda and Kuroki strains of *O. tsutsugamushi* were contaminated with *Mycoplasma hominis* and *M. orale* respectively. *M. hominis* and *M. orale* are 10 to 30% of contaminants of cell cultures (Table [2](#T2){ref-type="table"}) \[[@B11]\]. Previous reports showed that *M. fermentas, M. hyorhinis, M. arginini* and *Acholeplasma laidlawii* are the most common contaminants as well as *M. hominis* and *M. orale.* More than 90% of the contaminants were caused by these six mycoplasmas \[[@B11],[@B12]\]. The TaqMan PCR and the nested PCR can detect not only all the 6 most common contaminants also some other mycoplasmas. These facts suggested that the detection methods were very reliable to monitor mycoplasmas-contaminations in this study.

###### 

Major mycoplasmas, and their detection and sequencing methods in this study

  **Species**                                 **PCR for detection**   **PCR for Sequencing**^**d)**^                                                                  
  --------------------------------- --------- ----------------------- -------------------------------- --------------- ---------------------------------------------- ---------------
  Most common contaminant species                                                                                                                                      
  *Mycoplasma fermentans*           10%-20%   \+                      \+                               Match           human B cell lymphoma contaminants, 16054780   AY838558
  *Mycoplasma hyorhinis*            10%-40%   \+                      \+                               Match           HUB-1                                          NC_014448.1
  *Mycoplasma orale*                20%-30%   \+                      \+                               Partial Match   ATCC 23714D                                    gi\|315440428
  *Mycoplasma arginini*             20%-30%   No Data                 \+                               Partial Match   G230                                           gi\|290575476
  *Acholeplasma laidlawii*          5%-20%    \+                      \+                               Match           PG-8A                                          CP000896
  *Mycoplasma hominis*              10%-20%   \+                      \+                               Match           ATCC 23114                                     M57675
  Other species                                                                                                                                                        
  *Mycoplasma arthritidis*          No Data   \+                      No Data                          Match           158L3-1                                        NC_011025.1
  *Mycoplasma bovis*                No Data   \+                      No Data                          Match           PG45                                           NC_014760.1
  *Mycoplasma buccale*              No Data   \+                      No Data                          No data         \-                                             \-
  *Mycoplasma faucium*              No Data   \+                      No Data                          No data         \-                                             \-
  *Mycoplasma gallisepticum*        No Data   \+                      No Data                          Match           PG31                                           X16462
  *Mycoplasma genitalium*           No Data   \+                      \+                               Match           ATCC33530                                      X16463
  *Mycoplasma hyopneumoniae*        No Data   \+                      No Data                          Match           7448                                           NC_007332.1
  *Mycoplasma penetrans*            No Data   \+                      No Data                          Match           HF-2                                           NC_004432.1
  *Mycoplasma pneumoniae*           No Data   \+                      \+                               Match           FH                                             X55768
  *Mycoplasma primatum*             No Data   \+                      No Data                          No data         \-                                             \-
  *Mycoplasma salivarium*           No Data   \+                      \+                               Partial Match   ATCC 23064D                                    gi\|313575713
  *Ureaplasma parvum*               No Data   \+                      No Data                          Match           ATCC 33697                                     AF270770
  *Mycoplasma zalophi*              No Data   No Data                 No Data                          Match           CSL 4296                                       gi\|148536300
  *Mycoplasma mycoides*             No Data   No Data                 No Data                          Match           PG1                                            gi\|126252003
  *Mycoplasma capricolum*           No Data   No Data                 No Data                          Match           ATCC 27343                                     gi\|83319253
  *Mycoplasma agalactiae*           No Data   No Data                 No Data                          Match           PG2                                            gi\|148291314
  *Mycoplasma pyrum*                No Data   No Data                 \+                               No data         \-                                             \-

a\) Upper 6 species of mycoplasmas are the most common contaminants of cell cultures \[[@B11],[@B12]\].

b\) This broad-range TaqMan PCR can detect many species of mycoplasmas \[[@B22]\].

c\) This nested PCR is highly sensitive, and it is used to check for mycoplasma contamination in the Cell Bank of BioResource Centre, Riken Tsukuba Institute, Tsukuba, Ibaraki, Japan \[[@B21]\].

d\) PCR assay for sequencing of mycoplasmas designed in this study. Partial Match means that 2 or 3 of the total of 4 nested-PCR primers match to available regions of the *tuf* gene on the public database.

For elimination of mycoplasmas, we first cultured a contaminated, high virulent Ikeda strain of *O. tsutsugamushi* using L-929 cell in the culture medium containing lincomycin and ciprofloxacin and repeated the passages (Figure [1](#F1){ref-type="fig"}). Lincomycin and ciprofloxacin were used at 100, 10 and 1 μg/ml. However, ciprofloxacin at 100 μg/ml were cytotoxic against L-929 cell in the first assay and was omitted from the further analyses. We checked mycoplasma-contaminations and *O. tsutsugamushi-growth* at each passage by the two PCR based methods and/or an immunofluorescent (IF) staining (see Additional file [1](#S1){ref-type="supplementary-material"}). From the passage 1 to 2 with 10 μg/ml of lincomycin, the real-time PCR showed that mycoplasmas decreased, whereas *O. tsutsugamushi* did not decrease. At the passage 4 with the same concentration of lincomycin, the real-time PCR did not detect mycoplasmas, however the nested PCR still detected them. At the passage 5, both the real-time PCR and the nested PCR did not detect mycoplasmas, whereas the flourish growth of *O. tsutsugamushi* was observed by IF staining. We continued to culture with lincomycin until the passage 6. During following passages from 7 to 10 without lincomycin, mycoplasmas did not recover. These results clearly showed that mycoplasmas were completely eliminated from *O. tsutsugamushi*-infected cells. However, the cultivation with 100 μg/ml of lincomycin as well as 10 and 1 μg/ml of ciprofloxacin decreased both mycoplasmas and *O. tsutsugamushi-*growths, whereas the cultivation with 1 μg/ml of lincomycin did not influence the neither growths.

![**Illustrations of decontamination of mycoplasma-contaminated*O. tsutsugamushi*strains by repeating passage through cell cultures with antibiotics.** Ikeda is a high virulent strain, whereas Kuroki is a low virulent strain, which is difficult to propagate in mice. LCM: lincomycin, CPFX: ciprofloxacin, Myco: mycoplasmas, Ots: *O. tsutsugamushi.*](1471-2180-13-32-1){#F1}

By the same procedure of Ikeda strain, we cultured a contaminated, low virulent Kuroki strain of *O. tsutsugamushi* with lincomycin at 10 μg/ml (Figure [1](#F1){ref-type="fig"}). Mycoplasmas and *O. tsutsugamushi* were monitored by the nested PCR and the IF assay respectively (see Additional file [2](#S2){ref-type="supplementary-material"}). At the passage 8, the nested PCR did not detect mycoplasmas. We then continued to cultivate it with lincomycin until the passage 11. During following passages from 12 to 14 without lincomycin, mycoplasmas did not recover. These results showed that we successfully eliminated mycoplasmas also from the low virulent Kuroki strain. The elimination length of Kuroki strain was longer than that of Ikeda strain probably because numbers and/or antibiotics-susceptibility of the contaminated mycoplasmas were different. For further elimination of mycoplasmas from other strains of *O. tsutsugamushi*, we should first evaluate a maximum concentration of lincomycin that does not influence *O. tsutsugamushi-*growth, and then apply it for decontamination because maximum effects against mycoplasmas are necessary to eliminate them for a short time and to avoid producing lincomycin-resistant mycoplasmas \[[@B13]-[@B15]\] during repeating passages. Our additional assay showed that lincomycin at 25 μg/ml did not affect the growth (the virulent strain), whereas 50 μg/ml slightly decreased (did not inhibit) the growth in the IF assay (Table [3](#T3){ref-type="table"}). Many previous reports about antibiotics-susceptibilities of isolated mycoplasmas showed that MICs of lyncomycin against *M. hominis*, *M. fermentas* and *A. laidlawii*, which are the major contaminants, were less than 6 μg/ml (0.025 to 6 μg/ml) \[[@B5],[@B16]-[@B18]\]. In actual, a previous report showed that lincomycin at 50 μg/ml successfully eliminated the other major contaminants of mycoplasmas, *M. hyorhinis* and *M. hominis* from cell cultures \[[@B19]\]. However, a previous report showed that some isolates of *M. hyorhinis* were highly resistant to lyncomycin (MICs \> 100 μg/ml) \[[@B14]\] and a few reports showed that other species of mycoplasmas but not major species of contaminants were highly resistant to lyncomycin \[[@B13],[@B15]\]. Considering these facts, lincomycin at 50 μg/ml can possibly eliminate the contaminants from many of other contaminated strains of *O. tsutsugamushi*, although it might not be effective for all the cases.

###### 

**The growth of*O. tsutsugamushi*at the various concentrations of lincomycin**

                                  **Concentrations of lincomycin in the culture medium**                         
  ------------------------------- -------------------------------------------------------- ---------- ---------- -----------
                                  12.5 μg/ml                                               25 μg/ml   50 μg/ml   100 μg/ml
  *O. tsutsugamsuhi*-growth^a)^   +++                                                      +++        ++         \-

a\) A virulent Ikeda strain was cultivated using L-929 cell in the culture medium containing lyncomycin at the indicated concentrations. The growth was observed by the immunofluorescent staining.

Conclusions
===========

Our results showed an alternative method to eliminate mycoplasmas from the mycoplasma-contaminated strains of *O. tsutsugamushi* in place of *in vivo* passage through mice. Especially this new method works for the decontamination not only from the high virulent strain also from the low virulent strain of *O. tsutsugamushi, which* is difficult to propagate in mice. For further elimination, lincomycin at the limit concentration, which does not inhibit the growth of *O. tsutsugamushi*, can possibly eliminate most mycoplasmas from contaminated *O. tsutsugamushi* strains.

Methods
=======

Cell lines
----------

A mycoplasmas-free L-929 cell (a mouse fibroblast cell line, JCRB9003) \[[@B20]\] was grown in Eagle's minimum essential medium (MEM, Wako Co. Ltd., Tokyo, Japan) supplemented with 5 to 10% of mycoplasma-free, heat-inactivated FCS (Sigma-Aldrich Japan Co. LCC., Tokyo, Japan) at 37°C in 5% CO~2~.

Mycoplasmas-contaminated *O. tsutsugamushi* strains for elimination
-------------------------------------------------------------------

A mycoplasmas-contaminated high virulent Ikeda strain and a low virulent Kuroki strain of *O. tsutsugamushi* were used for elimination. These strains were accidentally contaminated during a long passage history probably because mycoplasmas-contaminated cell culture was used for propagation of these strains. The mycoplasma-free L-929 cell was used for propagation as mentioned in the previous section.

Detection and quantification of mycoplasmas
-------------------------------------------

Major mycoplasmas are listed in Table [2](#T2){ref-type="table"}. Upper 6 species are the most common contaminants in cell cultures \[[@B11],[@B12]\]. In order to monitor mycoplasmas, we extracted DNA from *O. tsutsugamushi*-infected L-929 cell with a commercial DNA extract kit (Tissue genomic DNA extraction mini kit, Favorgen biotech corporation, Ping-Tung, Taiwan) and detected mycoplasmas by two high sensitive and broad range PCR based methods for detection, the nested PCR \[[@B21]\] and the real-time PCR (TaqMan PCR) \[[@B22]\]. The nested PCR is used to check mycoplasma*-*contaminations in the Cell Bank of Bioresource Centre, Riken Tsukuba institute, Tsukuba, Ibaraki, Japan. For determination of mycoplasma species, we designed new sequencing primers against *tuf* gene (Table [2](#T2){ref-type="table"}). These designed primers matched *tuf* gene of 19 mycoplasmas on the public database. All the primers and the probe are listed in Table [4](#T4){ref-type="table"}.

###### 

Primers and probes for detection and sequencing in this study

  **Targets**                             **Assay**        **Name**          **Primers and probes**
  --------------------------------------- ---------------- ----------------- ----------------------------------------------------------
  Mycoplasmas                                                                 
  *tuf* gene^a)^                          real-time PCR    Mollicutes 414F   5\'-TCCAGGWCAYGCTGACTA-3\'
                                                           Mollicutes 541R   5\'-ATTTTWGGAACKCCWACTTG-3\'
                                                           Probe 451F^a)^    5\'-G[G]{.ul}TGCTG[C]{.ul}ACA[A]{.ul}ATGG[A]{.ul}TGG-3\'
  *tuf* gene                              Sequencing 1st   Myco-tuf-F1       5\'-HATHGGCCAYRTTGAYCAYGGKAAAA-3\'
                                                           Myco-tuf-F2       5\'-ATGATYACHGGDGCWGCHCAAATGGA-3\'
                                          Sequencing 2nd   Myco-tuf-R1       5\'-CCRCCTTCRCGRATDGAGAAYTT-3\'
                                                           Myco-tuf-R2       5\'-TKTRTGACGDCCACCTTCYTC-3\'
  16s-23s rRNA intergenic spacer region   nested PCR 1st   MCGpF11           5\'-ACACCATGGGAGYTGGTAAT-3\'
                                                           R23-1R            5\'-CTCCTAGTGCCAAGSCATYC-3\'
                                          nested PCR 2nd   R16-2             5\'-GTGSGGMTGGATCACCTCCT-3\'
                                                           MCGpR21           5\'-GCATCCACCAWAWACYCTT-3\'
  *Orientia tsutsugamushi*                                                    
  47kDa common antigen coding gene        real-time PCR    Ots-47k-F         5\'-AATTCGTCGTGGTATGTTAAATG-3\'
                                                           Ots-47k-R         5\'-AGCAATTCCACATTGTGCTG-3\'
                                                           Ots-47k-P ^b)^    5\'-TGCTTAATGAATTAACTCCAGAATT-3\'

a\) Locked nucleic acid (LNA) bases (underlined) and was synthesized with the fluorescent reporter 6-carboxyfluorescein (FAM) covalently coupled to the 5' end and a dark quencher to the 3' end.

b\) TaqMan probe was synthesized with the fluorescent reporter 6-carboxyfluorescein (FAM) covalently coupled to the 5' end and a dark quencher to the 3' end.

Detection of *O. tsutsugamushi*
-------------------------------

To monitor the growth of *O. tsutsugamushi*, we used a real-time PCR against the gene encoding 47kDa common antigen (Table [4](#T4){ref-type="table"}). We extracted DNA from *O. tsutsugamushi*-infected L-929 cell as mentioned in the previous section and performed the real-time PCR according to the general procedure \[[@B23]\]. We also used an IF staining to monitor the growth of *O. tsutsugamushi*. In this staining, human convalescent sera of a scrub typhus patient, which were permitted by the ethics committee (number 255), and anti-human antibody conjugated with AlexaFluor®488 (Life technologies Japan Ltd, Tokyo, Japan) were used. A part of the infected cells were harvested and fixed on a glass slide with ice cold acetone and then the slide was applied for the IF staining according to the previous reports \[[@B24]\].

Antibiotics
-----------

Lincomycin (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and ciprofloxacin (Wako Pure Chemical Industries, Ltd., Osaka, Japan) were used for elimination of mycoplasmas in this study. Kanamycin and gentamycin are routinely used for propagation of *O. tsutsugamushi* to avoid accidental bacterial contamination in our laboratory because they do not influence *O. tsutsugamushi*-growth \[[@B25]\].

Elimination of mycoplasmas from *O. tsutsugamushi*-infected cells with antibiotics
----------------------------------------------------------------------------------

We cultured the contaminated strains of *O. tsutsugamushi* using L-929 cell in the culture medium containing lincomycin and ciprofloxacin at 100, 10 and 1 μg/ml in 25cm2 tissue culture flask, and repeated passages about every seven days. At each passage, the infected cells were harvested. One-third of the harvested cells was used for the next inoculation, another one-third was used for DNA extraction, and the remaining one-third was frozen and stocked. Elimination of mycoplasmas was checked by the nested PCR and/or real-time PCR. The growth of *O. tsutsugamushi* was monitored by the real-time PCR and/or the IF staining.
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